Fulvestrant

Common brands: Faslodex, Cligavyx, Ibrance, Kisqali, Femara

Top reporter: Astrazeneca Pharmaceuticals Lp

Estrogen Receptor Antagonist [EPC]Kinase Inhibitor [EPC]Aromatase Inhibitor [EPC]RANK Ligand Inhibitor [EPC]Nucleoside Metabolic Inhibitor [EPC]
32,192
Total Reports
17,023
Serious Reports
4,876
Death Reports
30
Reported Reactions
Death Report Ratio: High (15.15%)

Patient Demographics

Male
338
Female
29,802

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Fulvestrant.

# Reaction Reports % of Total
1 MALIGNANT NEOPLASM PROGRESSION 4,113
7.7%
2 FATIGUE 4,102
7.7%
3 NAUSEA 2,948
5.6%
4 DEATH 2,707
5.1%
5 DIARRHOEA 2,542
4.8%
6 NEUTROPENIA 2,437
4.6%
7 WHITE BLOOD CELL COUNT DECREASED 2,159
4.1%
8 NEOPLASM PROGRESSION 2,128
4.0%
9 METASTASES TO BONE 2,089
3.9%
10 ASTHENIA 1,730
3.3%
11 PAIN 1,708
3.2%
12 METASTASES TO LIVER 1,689
3.2%
13 BREAST CANCER METASTATIC 1,604
3.0%
14 DYSPNOEA 1,596
3.0%
15 VOMITING 1,533
2.9%
16 DECREASED APPETITE 1,424
2.7%
17 ARTHRALGIA 1,397
2.6%
18 ALOPECIA 1,353
2.5%
19 DISEASE PROGRESSION 1,293
2.4%
20 OFF LABEL USE 1,282
2.4%
21 ANAEMIA 1,281
2.4%
22 RASH 1,233
2.3%
23 MALAISE 1,177
2.2%
24 DRUG INEFFECTIVE 1,169
2.2%
25 COUGH 1,103
2.1%
26 HEADACHE 1,103
2.1%
27 BACK PAIN 1,076
2.0%
28 DIZZINESS 1,064
2.0%
29 PYREXIA 1,043
2.0%
30 WEIGHT DECREASED 1,029
1.9%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.